-
Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
Oncoscience | July 22nd, 2015
The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe. Transactio...
-
Oncoscience AG and GenIlac agree on cooperation terms in Turkey
Oncoscience | July 7th, 2010
Oncoscience, Wedel and GenIlac, Ankara agree on cooperation in Turkey for Nimotuzumab(Theraloc®), an EGFr antibody, whi...
-
Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009
Oncoscience | October 9th, 2009
On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented. At ...
-
Funcrypta – Poster presentation at European Bioperspectives
Oncoscience | October 4th, 2008
Oncoscience AG is a member of the German Funcrypta project. Within the scope of this cooperation a poster will be presen...
-
Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer.
Oncoscience | April 22nd, 2008
Oncoscience AG announced that their anti-cancer drug Nimotuzumab (Theraloc®) has been designated an orphan drug by the ...
